TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00841828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study: NCT03375918

Intervention type: OTHER
Group type: OTHER
Intervention: CONSULT-BP Educational Intervention
Description: The CONSULT-BP intervention includes two, 180-minute, in-persons sessions 5 weeks apart. Each session has 3 parts: 1. Pre-Clinical Practice Simulation Learning; 2. Trainee Self-Assessments of implicit bias; and 3. In-Person Clinical Practice Simulations to practice communication skills, trigger reflection, and frame group-based reflections on bias.

Intervention type: OTHER
Group type: OTHER
Intervention: CONSULT-BP Educational Intervention
Description: The CONSULT-BP intervention includes two, 180-minute, in-persons sessions 5 weeks apart. Each session has 3 parts: 1. Pre-Clinical Practice Simulation Learning; 2. Trainee Self-Assessments of implicit bias; and 3. In-Person Clinical Practice Simulations to practice communication skills, trigger reflection, and frame group-based reflections on bias.

Intervention type: OTHER
Group type: OTHER
Intervention: CONSULT-BP Educational Intervention
Description: The CONSULT-BP intervention includes two, 180-minute, in-persons sessions 5 weeks apart. Each session has 3 parts: 1. Pre-Clinical Practice Simulation Learning; 2. Trainee Self-Assessments of implicit bias; and 3. In-Person Clinical Practice Simulations to practice communication skills, trigger reflection, and frame group-based reflections on bias.

Intervention type: OTHER
Group type: OTHER
Intervention: CONSULT-BP Educational Intervention
Description: The CONSULT-BP intervention includes two, 180-minute, in-persons sessions 5 weeks apart. Each session has 3 parts: 1. Pre-Clinical Practice Simulation Learning; 2. Trainee Self-Assessments of implicit bias; and 3. In-Person Clinical Practice Simulations to practice communication skills, trigger reflection, and frame group-based reflections on bias.
Study: NCT03988192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOC analysis
Description: VOC analysis in exhaled air with e-noses and mass spectrometry.
Study: NCT03294733

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: This ultrasound machine is owned by the department of orthopaedic surgery and is capable of up to 15 MHz image definition with its linear transducer
Study: NCT01354847

Intervention type: DEVICE
Intervention: Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)
Description: ex vivo platelet aggregation at several intraoperative and postoperative measuring points.
Study: NCT00766246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
Study: NCT00841828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Study: NCT03451214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Zinc
Description: 4 mg zinc from zinc biofortified wheat, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period
Study: NCT02522715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV
Study: NCT00766246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
Study: NCT02522715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01243970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Infusion dose 50 mcg / minute. On/off regimen in response to blood pressure (BP) readings every minute. Approximative 30 minutes treatment duration. Total dose 50 mcg - 1500 mcg \*~\* We will start the infusion after the spinal anaesthetic (see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 1500 mcg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: Infusion dose 4mg / minute. On/off regimen in response to blood pressure readings every minute. Approximative 30 minutes treatment duration. Total dose 4 mg - 120 mg. \*~\* We will start the infusion after the spinal anaesthetic(see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 120mg.
Study: NCT02365285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: 16 mg po prior to the infusion of intralipid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galantamine
Description: 16 mg po prior to the infusion of intralipid
Study: NCT02436356

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteoprobe-Reference Point Indentation (RPI)
Description: Diagnostic tool used for bone indentation to measure the ability of the tissue to resist microindentation (bone mineral strength).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Dual-energy X-ray absorptiometry (DXA) Scans
Description: Assessment of Fracture Risk

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Dual-energy X-ray absorptiometry (DXA) Scans
Description: Assessment of Fracture Risk

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Dual-energy X-ray absorptiometry (DXA) Scans
Description: Assessment of Fracture Risk

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Determines bound water and pore water of bone.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Determines bound water and pore water of bone.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Determines bound water and pore water of bone.
Study: NCT02365285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Capsule
Description: Placebo oral capsule prior to the infusion of intralipid/heparin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo oral capsule prior to the infusion of intralipid/heparin
Study: NCT03941431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jueyin granules
Description: Jueyin granules p.o. once a day for 8 weeks.
Study: NCT02365285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid
Description: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intralipid
Description: Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
Study: NCT02638506

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Salinex
Description: All patients will receive an equivalent volume of similar looking placebo to fentanyl (1.5 mcg/kg dose). This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
Study: NCT03185793

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: 1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks
Study: NCT03941431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jueyin granules
Description: Jueyin granules p.o. once a day for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jueyin granules
Description: Jueyin granules p.o. once a day for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moving cupping therapy
Description: Moving cupping therapy three times per week for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moving cupping therapy
Description: Moving cupping therapy three times per week for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moving cupping therapy
Description: Moving cupping therapy three times per week for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB-UVB therapy
Description: NB-UVB phototherapy three times per week for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB-UVB therapy
Description: NB-UVB phototherapy three times per week for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jueyin placebo granules
Description: Jueyin placebo granules p.o. once a day for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jueyin placebo granules
Description: Jueyin placebo granules p.o. once a day for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moving cupping placebo therapy
Description: Moving cupping placebo therapy three times per week for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moving cupping placebo therapy
Description: Moving cupping placebo therapy three times per week for 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB-UVB placebo phototherapy
Description: NB-UVB placebo phototherapy three times per week for 8 weeks.
Study: NCT03538158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Condition
Description: Participants will have access to Fittle Senior which will provide guided exercises and social support from other participants of the study.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: Participants will have a paper booklet with suggested exercises that they may choose to complete for the duration of the study.
Study: NCT01537510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR - Study of Technology to Accelerate Research
Description: In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.
Study: NCT02365285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparin
Description: heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
Study: NCT02110888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous peripheral nerve stimulation
Study: NCT01537510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR - Study of Technology to Accelerate Research
Description: In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STAR - Study of Technology to Accelerate Research
Description: In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.
Study: NCT02110888

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SCS Only
Study: NCT03185793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: 1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks
Study: NCT04754568

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Role-playing instructional design
Description: 60 minute traditional role-playing with standardized patient
Study: NCT03689270

Intervention type: PROCEDURE
Intervention: Subluxation
Description: One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete.

Intervention type: PROCEDURE
Intervention: Divide and conquer
Description: Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
Study: NCT04604028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide [Leavdo®]
Description: Complete remission and partial remission rate
Study: NCT03593720

Intervention type: PROCEDURE
Intervention: Measurement in Office
Description: Penile length and glans size in 3 dimensions

Intervention type: PROCEDURE
Intervention: Measurement in OR
Description: Penile length and glans size in 3 dimensions

Intervention type: PROCEDURE
Intervention: Measurement in OR
Description: Penile length and glans size in 3 dimensions
Study: NCT02582619

Intervention type: OTHER
Intervention: Focus groups, semistructured interviews and Delphi rounds

Intervention type: OTHER
Intervention: Focus groups, semistructured interviews and Delphi rounds

Intervention type: OTHER
Intervention: Focus groups, semistructured interviews and Delphi rounds

Intervention type: OTHER
Intervention: Focus groups, semistructured interviews and Delphi rounds
Study: NCT04650685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The novel Salvadora persica toothbrush
Description: The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Salvadora persica (miswak) chewing stick
Description: The Salvadora persica chewing stick will be used twice daily without the application of toothpaste. The Salvadora persica chewing sticks need to be prepared prior to use. A five-finger grip technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard toothbrush and toothpaste (control)
Description: The novel Salvadora persica toothbrush will be used twice daily without the application of toothpaste. Modified bass technique will be applied. A demonstration by another investigator will be done via video, written instructions and a tell-show-do method using typodont model.
Study: NCT01092572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin 40 mg per day orally for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 1 tablet once daily for 12 weeks
Study: NCT03683680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MPT Test
Description: molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLDN15/VIM Test
Description: molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
Study: NCT02454140

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Fixed five-fraction stereotactic radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Fixed five-fraction stereotactic radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Fixed five-fraction stereotactic radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Fixed five-fraction stereotactic radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Fixed five-fraction stereotactic radiotherapy
Study: NCT04286737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 6 times in 2 weeks.
Study: NCT03825692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zhizhu Kuanzhong Capsule
Description: Zhizhu Kuanzhong Capsule, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zhizhu Kuanzhong Placebo Capsule
Description: Placebo, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
Study: NCT03801746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadadustat
Description: Oral dose 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadadustat
Description: Oral dose 300 mg
Study: NCT01309581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 1-2 mg/kg IV as indicated for ECT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methohexital
Description: Methohexital 1 mg/kg IV as indicated for ECT
Study: NCT01926314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHENIX Neuromuscular Stimulation Therapy System device
Study: NCT03801746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadadustat
Description: Oral dose 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: IV Rifampin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Oral Probenecid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporins
Description: Oral Cyclosporine
Study: NCT03234439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myStrength
Description: myStrength is a digital self-care behavioral and wellness platform
Study: NCT00490022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydrotestosterone (DHT) gel (0.7%)
Description: DHT gel, 70 mg/day for one month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel for one month
Study: NCT00023686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Study: NCT01083498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablative fractional laser therapy
Description: 10,600 nm ablative fractional laser Irradiance: 10 mJ/microbeam. Coverage: 35-45%. Number of treatment sessions: 3
Study: NCT02221518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure & Response Prevention (EX/RP)
Description: Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD.
Study: NCT02144545

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bougie Size 33 Fr
Description: Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bougie Size 33 Fr
Description: Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bougie Size 42 Fr
Description: Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bougie Size 42 Fr
Description: Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distance pylorus 2 cm
Description: Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distance pylorus 2 cm
Description: Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distance pylorus 5 cm
Description: Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distance pylorus 5 cm
Description: Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
Study: NCT03371173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric maltol 30 mg (Feraccru®)
Description: Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
Study: NCT03933553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy with essential oil
Description: the aromatherapy by fragrance inhalation
Study: NCT01926314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual home care without device
Study: NCT03933553

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy with essential oil
Description: the aromatherapy by fragrance inhalation
Study: NCT00794235

Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib (Nexavar), Dacarbazine (DTIC)
Description: Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.~DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42.
Study: NCT02176434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney and hematopoietic stem cell transplantation
Description: Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell